Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 22, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Amgen
- Interventions being studied
- Drug: AMG 510; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Men or women greater than or equal to 18 years old.
- ECOG ≤ 1
- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment
- Active brain metastases
- Myocardial infarction within 6 months of study day 1
- Gastrointestinal (GI) tract disease causing the inability to take oral medication
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pacific Cancer Medical Center IncAnaheim, California
- City of Hope National Medical CenterDuarte, California
- Pacific Shores Medical Group Long BeachLong Beach, California
- University of California Los AngelesLos Angeles, California
- University of California Los AngelesLos Angeles, California
- University of California at Davis Medical CenterSacramento, California
- Ridley Tree Cancer CenterSanta Barbara, California
- University of California San Francisco Mission HallStanford, California
- Harbor University of California Los Angeles Medical CenterTorrance, California
- Rocky Mountain Cancer CentersDenver, Colorado
- Danbury HospitalNorwalk, Connecticut
- Medical Oncology Hematology Consultants Helen F Graham Cancer CenterNewark, Delaware
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 22, 2026. Always confirm current availability with the study team.